Main results from Phase III study of inhaled ciclesonide in Covid-19 presented by company
In the study of non-hospitalised patients 12 years of age and older with symptomatic COVID-19 infection, ciclesonide was not associated with a statistically significant improvement vs placebo in time to alleviation of Covid-19 related symptoms (primary endpoint).
Source:
Biospace Inc.
Resource links:
Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19
SPS commentary:
Interim results from the National Institute for Health Research (NIHR) supported PRINCIPLE trial show that inhaled budesonide (typically used and licensed in the management of asthma) can reduce the recovery time (3-day median benefit) for COVID-19 positive patients being managed within primary care. The impact on hospitalisation rates or mortality has not been established, but the evaluation is ongoing. At this point in time, inhaled budesonide is not being recommended for routine use, but can be considered to be prescribed (off-label) by healthcare professionals on a case-by-case basis using the information described in an Interim Position Statement and the interim results from the PRINCIPLE trial (pre-print).